Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 160

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 160
---
     | Position                                                       |
| Lloyd M. Segal*^             |     | Former President and Chief Executive Officer                   |
| Maria Koehler, M.D., Ph.D.*^ |     | Former Executive Vice President, Chief Medical Officer         |
| Michael Zinda, Ph.D.*        |     | Executive Vice President, Chief Scientific Officer             |
| Steve Forte                  |     | President, Chief Executive Officer and Chief Financial Officer |
| Sandra Alves                 |     | Senior Vice President, Chief Accounting Officer                |

Assumptions The potential payments and benefits to directors and executive officers in the narrative and tables below are, unless otherwise noted, based on the following facts and assumptions:

| • |     | the relevant price per Common Share is $1.82, which is the per share Cash Amount; |

| • |     | no amount will be payable under the CVRs; |

| • |     | the executive officers are terminated without “cause” immediately following the assumed Effective 
 Time;                                                                                             |

99

Accordingly, the amounts set forth in the narrative and tables below are estimates based on multiple assumptions that may or may not actually occur, including the assumptions described above. Some of the assumptions are based on events which may not occur or other contingencies and, as a result, the actual amounts received by a director or executive officer may differ materially from the amounts shown below. Certain of the amounts shown below have also been rounded to the nearest whole number. Additionally, amounts paid in Canadian dollars have been converted to U.S. dollars at the average exchange rate of $0.7143 for November 18, 2025, based on Bank of Canada average exchange rates. Equity Awards As of the Effective Time, all vested and unvested equity awards held by our directors and executive officers will be treated as follows and described in more detail under “ The Arrangement.” Each Option outstanding as of the Effective Time (whether vested or unvested) will be deemed to be unconditionally vested and exercisable and, without any further action by or on behalf of the Optionholder, each in-the-moneyOption (an Option which has a per-shareexercise price that is less than the Cash Amount) will be deemed to be assigned and surrendered to the Company in exchange for (i) an amount in cash from the Company equal to the Cash Amount less the applicable exercise price in respect of such Option, and (ii) one CVR, and such Option will immediately be canceled. Out-of-the-moneyOptions (Options with a per